These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16312183)

  • 1. Letter. In vitro phenotypic susceptibility to nucleoside reverse transcriptase inhibitors of HIV-2 isolates with the Q151M mutation in the reverse transcriptase gene.
    Damond F; Collin G; Matheron S; Peytavin G; Campa P; Delarue S; Taieb A; Bénard A; Chêne G; Brun-Vézinet F; Descamps D;
    Antivir Ther; 2005; 10(7):861-5. PubMed ID: 16312183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France.
    Colson P; Henry M; Tivoli N; Gallais H; Gastaut JA; Moreau J; Tamalet C
    J Med Virol; 2005 Mar; 75(3):381-90. PubMed ID: 15648062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of selection of K65R and Q151M mutations in HIV-2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen.
    Descamps D; Damond F; Matheron S; Collin G; Campa P; Delarue S; Pueyo S; Chêne G; Brun-Vézinet F;
    J Med Virol; 2004 Oct; 74(2):197-201. PubMed ID: 15332266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.
    Van Laethem K; Pannecouque C; Vandamme AM
    Infect Genet Evol; 2007 Sep; 7(5):600-3. PubMed ID: 17567542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.
    Ntemgwa M; Wainberg MA; Oliveira M; Moisi D; Lalonde R; Micheli V; Brenner BG
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3861-9. PubMed ID: 17724152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.
    Witvrouw M; Pannecouque C; Switzer WM; Folks TM; De Clercq E; Heneine W
    Antivir Ther; 2004 Feb; 9(1):57-65. PubMed ID: 15040537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.
    Maniar JK; Damond F; Kamath RR; Mandalia S; Surjushe A
    Int J STD AIDS; 2006 Nov; 17(11):781-2. PubMed ID: 17062187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.
    Qari SH; Winters M; Vandamme AM; Merigan T; Heneine W
    Antivir Ther; 2002 Jun; 7(2):131-9. PubMed ID: 12212925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
    Liu J; Yue J; Wu S; Yan Y
    Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E.
    Lolekha R; Sirivichayakul S; Siangphoe U; Pancharoen C; Kaewchana S; Apateerapong W; Mahanontharit A; Chotpitayasunondh T; Ruxrungtham K; Phanuphak P; Ananworanich J
    Clin Infect Dis; 2005 Jan; 40(2):309-12. PubMed ID: 15655753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
    Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
    J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
    Gallant JE; Gerondelis PZ; Wainberg MA; Shulman NS; Haubrich RH; St Clair M; Lanier ER; Hellmann NS; Richman DD
    Antivir Ther; 2003 Dec; 8(6):489-506. PubMed ID: 14760883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses.
    Deuzing IP; Charpentier C; Wright DW; Matheron S; Paton J; Frentz D; van de Vijver DA; Coveney PV; Descamps D; ; Boucher CA; Beerens N
    J Virol; 2015 Jan; 89(1):833-43. PubMed ID: 25355888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors.
    Geretti AM
    AIDS Rev; 2006; 8(4):210-20. PubMed ID: 17219736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues.
    Roquebert B; Marcelin AG
    J Antimicrob Chemother; 2008 May; 61(5):973-5. PubMed ID: 18325896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.